Treatment Response to Sofosbuvir and Ribavirin in Chronic Hepatitis C Patients and Comparison of Naive and Treatment Experienced Patients

  • Muhammad Ikhlaq Final year M.B.B.S student Rawalpindi Medical College, Rawalpindi
  • Maryam Jalil Woman medical officer at THQ Hospital, Fateh Jang
  • Syed Dawar Woman medical officer at THQ Hospital, Fateh Jang
  • Muhammad Ashraf House Officer, RMU Allied Hospitals, Rawalpindi
Keywords: End treatment response, Treatment response, Chronic hepatitis C, Sofosbuvir, Ribavirin, Genotype

Abstract

Background: Sofosbuvir is on the world organization’s list of essential medicines, the most effective and safe medicines needed in health system. It plays a special role in treatment of chronic hepatitis C and offers many advantages due to its high potency, low side effects, oral administration, and high barrier to resistance.

Objectives: To compare the treatment response in treatment naive and treatment experienced chronic hepatitis C patients treated with sofosbuvir and ribavirin to determine the efficacy of this drug combination.

Methods: In this experimental study 104 chronic hepatitis C patients with positive polymerase chain reaction (PCR) for hepatitis C virus (HCV) and high alanine aminotransferase (ALT) levels were included. Out of them 66 (63.5%) were treatment naive (received treatment for the first time) and 38 (36.5%) were treatment experienced. Sofosbuvir 400mg once a day in combination with ribavirin was given for 6 months and treatment responses were noted at 4, 12 and 24 weeks. SPSS version 21 was used to analyze the data.

Results: The end treatment response in 104 chronic hepatitis C patients was calculated in which 99 (95.2%) patients responded to the therapy. 63 (95.5%) treatment naive patients and 36 (94.7%) treatment experienced responded to the therapy. End treatment response (ETR) in chronic hepatitis C patients to sofosbuvir and ribavirin was irrespective to their gender and genotypes and test of significance came out as insignificant (p > 0.05).

Conclusion: Sofosbuvir is effective for both treatment naive and treatment experienced chronic hepatitis C patients. This regimen is equally effective for both genders and all genotypes of hepatitis C.

Keywords: , , , , , .

Published
2018-12-29
How to Cite
1.
Ikhlaq M, Jalil M, Dawar S, Ashraf M. Treatment Response to Sofosbuvir and Ribavirin in Chronic Hepatitis C Patients and Comparison of Naive and Treatment Experienced Patients. JRMC [Internet]. 29Dec.2018 [cited 8May2021];22(S-1):19-2. Available from: https://journalrmc.com/index.php/JRMC/article/view/991